Sorafenib with or without everolimus in patients with unresectable hepatocellular carcinoma (HCC): A randomized multicenter phase II trial (SAKK 77/08 and SASL 29).
Dieter Koeberle(Kantonsspital St. Gallen), G. Bodoky(Unified Szent István and Szent László Hospital), Jonas Feilchenfeld(Hôpital du Valais), Gyula Demeter(Unified Szent István and Szent László Hospital), Michael Montemurro(University Hospital of Lausanne), Ivana Cvijetic(Swiss Group For Clinical Cancer Research), B. Tschanz, Piercarlo Saletti(Institute of Oncology Research), Dorothea Wagner(University of Lausanne), Markus Peck‐Radosavljevic(Klinikum Klagenfurt), Gábor Lakatos(Unified Szent István and Szent László Hospital), Qiyu Li(Army Medical University), Jean‐François Dufour(Universidad Iberoamericana), Panagiotis Samaras(University Hospital of Zurich), Arnaud Roth(Hôpital Beau-Séjour), Daniel Horber(Kantonsspital St. Gallen), Karin Ribi, Michael Buehlmann(University Hospital of Bern), Daniel Rauch(Washington University in St. Louis)
Cited by 5
Related Papers
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data
|Journal of Clinical Oncology|2006|1.2k